Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Mar 22;2(1):190-208.
doi: 10.3390/cancers2010190.

Cancer biomarkers: are we ready for the prime time?

Alok Mishra  1 , Mukesh Verma
Affiliations

Cancer biomarkers: are we ready for the prime time?

Alok Mishra et al. Cancers (Basel). .

Abstract

A biomarker is a characteristic that is objectively measured and evaluated as an indicator of normal biologic processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention. In cancer, a biomarker refers to a substance or process that is indicative of the presence of cancer in the body. A biomarker might be either a molecule secreted by a tumor or it can be a specific response of the body to the presence of cancer. Genetic, epigenetic, proteomic, glycomic, and imaging biomarkers can be used for cancer diagnosis, prognosis and epidemiology. These markers can be assayed in non-invasively collected biofluids. However, few cancer biomarkers are highly sensitive and specific for cancer detection at the present time. Consequently, biomarkers are not yet ready for routine use due to challenges in their clinical validation for early disease detection, diagnosis and monitoring to improve long-term survival of patients.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Classification of Biomarkers.
See this image and copyright information in PMC

References

    1. Gold P., Freedman S.O. Demonstration of tumor-specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques. J. Exp. Med. 1965;121:439–462. doi: 10.1084/jem.121.3.439. - DOI - PMC - PubMed
    1. Golub T.R., Slonim D.K., Tamayo P., Huard C., Gaasenbeek M., Mesirov J.P., Coller H., Loh M.L., Downing J.R., Caligiuri M.A., Bloomfield C.D., Lander E.S. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science. 1999;286:531–537. doi: 10.1126/science.286.5439.531. - DOI - PubMed
    1. Barry M.J. PSA screening for prostate cancer: the current controversy–a viewpoint. Patient outcomes research team for prostatic diseases. Ann. Oncol. 1998;9:1279–1282. doi: 10.1093/oxfordjournals.annonc.a010952. - DOI - PubMed
    1. Barry M.J. The PSA Conundrum. Arch. Intern. Med. 2006;9:7–8. doi: 10.1001/archinte.166.1.7. - DOI - PubMed
    1. Hoffman R.M., Couper M.P., Zikmund-Fisher B.J., Levin C.A., McNaughton-Collins M., Helitzer D.L., VanHoewyk J., Barry M.J. Prostate cancer screening decisions: results from the National Survey of Medical Decisions (DECISIONS study) Arch. Intern. Med. 2009;169:1611–1618. doi: 10.1001/archinternmed.2009.262. - DOI - PubMed

LinkOut - more resources